Business
Peijia Medical Announces 2025 Annual Results
Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its annual results for the year ended December 31, 2025 on March 25, 2026.
About this update from Peijia Medical Ltd.
[{"type":"text","content":"SUZHOU, China, March 26, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its annual results for the year ended December 31, 2025 on March 25, 2026.","length":284,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Peijia Medical)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Peijia Medical)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/e378995a692ee57ba72652d9104b47a3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dbXIVWIrXGKvcuM6iNOwmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5Nw--/https://media.zenfs.com/en/prnewswire.com/e378995a692ee57ba72652d9104b47a3","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2166853/PEIJIA_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"During the year, the Group delivered steady revenue growth and continued improvement in operating efficiency, while advancing multiple key pipeline programs. Against a dynamic industry backdrop, the Group's core business demonstrated increasingly resilience. The Neurointerventional Business emerged as a stronger earnings contributor, while the Transcatheter Valve Therapeutic Business continued to expand its platform, enhance commercialization capabilities and improve its profitability profile.","length":502,"tagName":"p"},{"type":"text","content":"Steady Growth with Improving Profitability Profile","length":50,"tagName":"p"},{"type":"text","content":"For the year ended December 31, 2025, the Group recorded total revenue of RMB712.9 million, representing a year-on-year increase of 15.8%. Revenue contribution remained balanced, with TAVR-related products accounting for 40.7% and neurointerventional products accounting for 59.3% of total revenue.","length":298,"tagName":"p"},{"type":"text","content":"While maintaining a relatively stable gross margin, the Group continued to strengthen cost discipline and improve operating efficiency, supported by scale expansion and more focused resource allocation. Excluding the losses attributable to the entities comprising the Future Technology Business [1], the Group's adjusted loss for the year narrowed by 44.1% year on year to RMB110.5...